The Bipolar Illness Onset study: research protocol for the BIO cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The Bipolar Illness Onset study : research protocol for the BIO cohort study. / Kessing, Lars Vedel; Munkholm, Klaus; Faurholt-Jepsen, Maria; Miskowiak, Kamilla Woznica; Nielsen, Lars Bo; Frikke-Schmidt, Ruth; Ekstrøm, Claus Thorn; Winther, Ole; Pedersen, Bente Klarlund; Poulsen, Henrik Enghusen; McIntyre, Roger S.; Kapczinski, Flavio; Gattaz, Wagner F.; Bardram, Jakob; Frost, Mads; Mayora, Oscar; Knudsen, Gitte Moos; Phillips, Mary; Vinberg, Maj.

In: BMJ Open, Vol. 7, No. 6, e015462, 2017.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Kessing, LV, Munkholm, K, Faurholt-Jepsen, M, Miskowiak, KW, Nielsen, LB, Frikke-Schmidt, R, Ekstrøm, CT, Winther, O, Pedersen, BK, Poulsen, HE, McIntyre, RS, Kapczinski, F, Gattaz, WF, Bardram, J, Frost, M, Mayora, O, Knudsen, GM, Phillips, M & Vinberg, M 2017, 'The Bipolar Illness Onset study: research protocol for the BIO cohort study', BMJ Open, vol. 7, no. 6, e015462. https://doi.org/10.1136/bmjopen-2016-015462

APA

Kessing, L. V., Munkholm, K., Faurholt-Jepsen, M., Miskowiak, K. W., Nielsen, L. B., Frikke-Schmidt, R., ... Vinberg, M. (2017). The Bipolar Illness Onset study: research protocol for the BIO cohort study. BMJ Open, 7(6), [e015462]. https://doi.org/10.1136/bmjopen-2016-015462

Vancouver

Kessing LV, Munkholm K, Faurholt-Jepsen M, Miskowiak KW, Nielsen LB, Frikke-Schmidt R et al. The Bipolar Illness Onset study: research protocol for the BIO cohort study. BMJ Open. 2017;7(6). e015462. https://doi.org/10.1136/bmjopen-2016-015462

Author

Kessing, Lars Vedel ; Munkholm, Klaus ; Faurholt-Jepsen, Maria ; Miskowiak, Kamilla Woznica ; Nielsen, Lars Bo ; Frikke-Schmidt, Ruth ; Ekstrøm, Claus Thorn ; Winther, Ole ; Pedersen, Bente Klarlund ; Poulsen, Henrik Enghusen ; McIntyre, Roger S. ; Kapczinski, Flavio ; Gattaz, Wagner F. ; Bardram, Jakob ; Frost, Mads ; Mayora, Oscar ; Knudsen, Gitte Moos ; Phillips, Mary ; Vinberg, Maj. / The Bipolar Illness Onset study : research protocol for the BIO cohort study. In: BMJ Open. 2017 ; Vol. 7, No. 6.

Bibtex

@article{9d237beccef546fa9ee148ce3f0ec277,
title = "The Bipolar Illness Onset study: research protocol for the BIO cohort study",
abstract = "Introduction Bipolar disorder is an often disabling mental illness with a lifetime prevalence of 1{\%}-2{\%}, a high risk of recurrence of manic and depressive episodes, a lifelong elevated risk of suicide and a substantial heritability. The course of illness is frequently characterised by progressive shortening of interepisode intervals with each recurrence and increasing cognitive dysfunction in a subset of individuals with this condition. Clinically, diagnostic boundaries between bipolar disorder and other psychiatric disorders such as unipolar depression are unclear although pharmacological and psychological treatment strategies differ substantially. Patients with bipolar disorder are often misdiagnosed and the mean delay between onset and diagnosis is 5-10 years. Although the risk of relapse of depression and mania is high it is for most patients impossible to predict and consequently prevent upcoming episodes in an individual tailored way. The identification of objective biomarkers can both inform bipolar disorder diagnosis and provide biological targets for the development of new and personalised treatments. Accurate diagnosis of bipolar disorder in its early stages could help prevent the long-term detrimental effects of the illness. The present Bipolar Illness Onset study aims to identify (1) a composite blood-based biomarker, (2) a composite electronic smartphone-based biomarker and (3) a neurocognitive and neuroimaging-based signature for bipolar disorder. Methods and analysis The study will include 300 patients with newly diagnosed/first-episode bipolar disorder, 200 of their healthy siblings or offspring and 100 healthy individuals without a family history of affective disorder. All participants will be followed longitudinally with repeated blood samples and other biological tissues, self-monitored and automatically generated smartphone data, neuropsychological tests and a subset of the cohort with neuroimaging during a 5 to 10-year study period. Ethics and dissemination The study has been approved by the Local Ethical Committee (H-7-2014-007) and the data agency, Capital Region of Copenhagen (RHP-2015-023), and the findings will be widely disseminated at international conferences and meetings including conferences for the International Society for Bipolar Disorders and the World Federation of Societies for Biological Psychiatry and in scientific peer-reviewed papers. Trial registration number NCT02888262.",
keywords = "biomarker, bipolar disorder, cognition, Depression and mood disorders, MRI scanning, smartphone",
author = "Kessing, {Lars Vedel} and Klaus Munkholm and Maria Faurholt-Jepsen and Miskowiak, {Kamilla Woznica} and Nielsen, {Lars Bo} and Ruth Frikke-Schmidt and Ekstr{\o}m, {Claus Thorn} and Ole Winther and Pedersen, {Bente Klarlund} and Poulsen, {Henrik Enghusen} and McIntyre, {Roger S.} and Flavio Kapczinski and Gattaz, {Wagner F.} and Jakob Bardram and Mads Frost and Oscar Mayora and Knudsen, {Gitte Moos} and Mary Phillips and Maj Vinberg",
year = "2017",
doi = "10.1136/bmjopen-2016-015462",
language = "English",
volume = "7",
journal = "B M J Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "6",

}

RIS

TY - JOUR

T1 - The Bipolar Illness Onset study

T2 - research protocol for the BIO cohort study

AU - Kessing, Lars Vedel

AU - Munkholm, Klaus

AU - Faurholt-Jepsen, Maria

AU - Miskowiak, Kamilla Woznica

AU - Nielsen, Lars Bo

AU - Frikke-Schmidt, Ruth

AU - Ekstrøm, Claus Thorn

AU - Winther, Ole

AU - Pedersen, Bente Klarlund

AU - Poulsen, Henrik Enghusen

AU - McIntyre, Roger S.

AU - Kapczinski, Flavio

AU - Gattaz, Wagner F.

AU - Bardram, Jakob

AU - Frost, Mads

AU - Mayora, Oscar

AU - Knudsen, Gitte Moos

AU - Phillips, Mary

AU - Vinberg, Maj

PY - 2017

Y1 - 2017

N2 - Introduction Bipolar disorder is an often disabling mental illness with a lifetime prevalence of 1%-2%, a high risk of recurrence of manic and depressive episodes, a lifelong elevated risk of suicide and a substantial heritability. The course of illness is frequently characterised by progressive shortening of interepisode intervals with each recurrence and increasing cognitive dysfunction in a subset of individuals with this condition. Clinically, diagnostic boundaries between bipolar disorder and other psychiatric disorders such as unipolar depression are unclear although pharmacological and psychological treatment strategies differ substantially. Patients with bipolar disorder are often misdiagnosed and the mean delay between onset and diagnosis is 5-10 years. Although the risk of relapse of depression and mania is high it is for most patients impossible to predict and consequently prevent upcoming episodes in an individual tailored way. The identification of objective biomarkers can both inform bipolar disorder diagnosis and provide biological targets for the development of new and personalised treatments. Accurate diagnosis of bipolar disorder in its early stages could help prevent the long-term detrimental effects of the illness. The present Bipolar Illness Onset study aims to identify (1) a composite blood-based biomarker, (2) a composite electronic smartphone-based biomarker and (3) a neurocognitive and neuroimaging-based signature for bipolar disorder. Methods and analysis The study will include 300 patients with newly diagnosed/first-episode bipolar disorder, 200 of their healthy siblings or offspring and 100 healthy individuals without a family history of affective disorder. All participants will be followed longitudinally with repeated blood samples and other biological tissues, self-monitored and automatically generated smartphone data, neuropsychological tests and a subset of the cohort with neuroimaging during a 5 to 10-year study period. Ethics and dissemination The study has been approved by the Local Ethical Committee (H-7-2014-007) and the data agency, Capital Region of Copenhagen (RHP-2015-023), and the findings will be widely disseminated at international conferences and meetings including conferences for the International Society for Bipolar Disorders and the World Federation of Societies for Biological Psychiatry and in scientific peer-reviewed papers. Trial registration number NCT02888262.

AB - Introduction Bipolar disorder is an often disabling mental illness with a lifetime prevalence of 1%-2%, a high risk of recurrence of manic and depressive episodes, a lifelong elevated risk of suicide and a substantial heritability. The course of illness is frequently characterised by progressive shortening of interepisode intervals with each recurrence and increasing cognitive dysfunction in a subset of individuals with this condition. Clinically, diagnostic boundaries between bipolar disorder and other psychiatric disorders such as unipolar depression are unclear although pharmacological and psychological treatment strategies differ substantially. Patients with bipolar disorder are often misdiagnosed and the mean delay between onset and diagnosis is 5-10 years. Although the risk of relapse of depression and mania is high it is for most patients impossible to predict and consequently prevent upcoming episodes in an individual tailored way. The identification of objective biomarkers can both inform bipolar disorder diagnosis and provide biological targets for the development of new and personalised treatments. Accurate diagnosis of bipolar disorder in its early stages could help prevent the long-term detrimental effects of the illness. The present Bipolar Illness Onset study aims to identify (1) a composite blood-based biomarker, (2) a composite electronic smartphone-based biomarker and (3) a neurocognitive and neuroimaging-based signature for bipolar disorder. Methods and analysis The study will include 300 patients with newly diagnosed/first-episode bipolar disorder, 200 of their healthy siblings or offspring and 100 healthy individuals without a family history of affective disorder. All participants will be followed longitudinally with repeated blood samples and other biological tissues, self-monitored and automatically generated smartphone data, neuropsychological tests and a subset of the cohort with neuroimaging during a 5 to 10-year study period. Ethics and dissemination The study has been approved by the Local Ethical Committee (H-7-2014-007) and the data agency, Capital Region of Copenhagen (RHP-2015-023), and the findings will be widely disseminated at international conferences and meetings including conferences for the International Society for Bipolar Disorders and the World Federation of Societies for Biological Psychiatry and in scientific peer-reviewed papers. Trial registration number NCT02888262.

KW - biomarker

KW - bipolar disorder

KW - cognition

KW - Depression and mood disorders

KW - MRI scanning

KW - smartphone

U2 - 10.1136/bmjopen-2016-015462

DO - 10.1136/bmjopen-2016-015462

M3 - Journal article

C2 - 28645967

AN - SCOPUS:85021423333

VL - 7

JO - B M J Open

JF - B M J Open

SN - 2044-6055

IS - 6

M1 - e015462

ER -

ID: 181418280